Clinical Trial Update: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

A pediatric Phase 1/2 trial of the radiopharmaceutical 67Cu-SARTATE for high-risk, relapsed, or refractory neuroblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 67Cu-SARTATE (Cu-67 labeled SARTATE)

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Neuroblastoma, Relapsed Neuroblastoma | Phase 1, Phase 2 | Status: TERMINATED